- Quantifying Through-Space Substituent Effects
-
The description of substituents as electron donating or withdrawing leads to a perceived dominance of through-bond influences. The situation is compounded by the challenge of separating through-bond and through-space contributions. Here, we probe the experimental significance of through-space substituent effects in molecular interactions and reaction kinetics. Conformational equilibrium constants were transposed onto the Hammett substituent constant scale revealing dominant through-space substituent effects that cannot be described in classic terms. For example, NO2 groups positioned over a biaryl bond exhibited similar influences as resonant electron donors. Meanwhile, the electro-enhancing influence of OMe/OH groups could be switched off or inverted by conformational twisting. 267 conformational equilibrium constants measured across eleven solvents were found to be better predictors of reaction kinetics than calculated electrostatic potentials, suggesting utility in other contexts and for benchmarking theoretical solvation models.
- Adam, Catherine,Burns, Rebecca J.,Cockroft, Scott L.,Mati, Ioulia K.,Muchowska, Kamila B.
-
supporting information
p. 16717 - 16724
(2020/07/24)
-
- Photoarylation of Pyridines Using Aryldiazonium Salts and Visible Light: An EDA Approach
-
A metal-free methodology for the photoarylation of pyridines, in water, is described giving 2 and 4-arylated-pyridines in yields up to 96percent. The scope of the aryldiazonium salts is presented showing important results depending on the nature and position of the substituent group in the diazonium salt, that is, electron-donating or electron-withdrawing in the ortho, meta, or para positions. Further heteroaromatics were also successfully photoarylated. Mechanistic studies and comparison between our methodology and similar metal-catalyzed procedures are presented, suggesting the occurrence of a visible-light EDA complex which generates the aryl radical with no need for an additional photocatalyst.
- Bartolomeu, Aloisio De A.,Brocksom, Timothy J.,De Oliveira, Kleber T.,No?l, Timothy,Silva, Rodrigo C.
-
-
- DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS
-
The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.
- -
-
Paragraph 69; 72; 77
(2018/12/02)
-
- Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution
-
Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CP55,940-induced intracellular calcium mobilization and [35S]GTP-γ-S binding while enhancing [3H]CP55,940 binding to the CB1 receptor. Structure-activity relationship studies revealed that the pyridinyl ring of 2 could be replaced by other aromatic rings and the pyrrolidinyl ring is not required for CB1 allosteric modulation. 34 (RTICBM-74) had similar potencies as 2 in all in vitro assays but showed significantly improved metabolic stability to rat liver microsomes. More importantly, 34 was more effective than 2 in attenuating the reinstatement of extinguished cocaine-seeking behavior in rats, demonstrating the potential of this diarylurea series as promising candidates for the development of relapse treatment of cocaine addiction.
- Nguyen, Thuy,German, Nadezhda,Decker, Ann M.,Langston, Tiffany L.,Gamage, Thomas F.,Farquhar, Charlotte E.,Li, Jun-Xu,Wiley, Jenny L.,Thomas, Brian F.,Zhang, Yanan
-
p. 7410 - 7424
(2017/09/22)
-
- Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus
-
The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described.
- Lizarzaburu, Mike,Turcotte, Simon,Du, Xiaohui,Duquette, Jason,Fu, Angela,Houze, Jonathan,Li, Leping,Liu, Jinqian,Reagan, Jeff,Yu, Ming,Medina, Julio C.,Murakoshi, Michiko,Oda, Kozo,Okuyama, Ryo,Nara, Futoshi
-
p. 5942 - 5947,6
(2020/07/30)
-
- PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS
-
Provided herein are compounds of formula I: wherein A, B, X, R1 , R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions
- -
-
Page/Page column 108
(2010/09/03)
-
- Iron-mediated direct suzuki-miyaura reaction: A new method for the ortho -arylation of pyrrole and pyridine
-
(Figure presented) The first example of an iron-mediated direct Suzuki-Miyaura reaction between N-heterocyclic compounds and arylboronic acids is described, and both electron-rich and electron-deficient heteroarenes can be successfully used for the coupling reaction.
- Wen, Jun,Qin, Song,Ma, Li-Fang,Dong, Liang,Zhang, Ji,Liu, Shan-Shan,Duan, Yi-Shu,Chen, Shan-Yong,Hu, Chang-Wei,Yu, Xiao-Qi
-
supporting information; experimental part
p. 2694 - 2697
(2010/09/03)
-
- Structurally simple inhibitors of lanosterol 14α-demethylase are efficacious in a rodent model of acute Chagas disease
-
We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14α-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T. cruzi amastigotes in vitro with values of EC 50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.
- Suryadevara, Praveen Kumar,Olepu, Srinivas,Lockman, Jeffrey W.,Ohkanda, Junko,Karimi, Mandana,Verlinde, Christophe L. M. J.,Kraus, James M.,Schoepe, Jan,Van Voorhis, Wesley C.,Hamilton, Andrew D.,Buckner, Frederick S.,Gelb, Michael H.
-
experimental part
p. 3703 - 3715
(2010/04/24)
-
- Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
-
A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to amino or pyridylamino cyclobutane derivatives.
- -
-
-
- Potassium peroxodisulfate: A convenient oxidizing agent for aromatization of 1,4-dihydropyridines
-
A series of 13 different 4-substituted 2,6-dimethyl-3,5-diethoxycarbonyl)-1,4-dihydropyridines have been oxidized to pyridine derivatives by potassium peroxodisulfate in dry and wet acetonitrile solution at reflux condition. Formation of two kinds of products has been observed depending on the type of 4-substituent. Addition of water affects only the rate of oxidation.
- Memarian,Mohammadpoor-Baltork,Sadeghi,Samani
-
p. 727 - 728
(2007/10/03)
-
- 2-Oxo-1,2-(dihydropyridyl)-2H-1-benzopyrans
-
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof: STR1 wherein Y, R2, R3, R4, R5, R6, R7 , a and b are as defined in the Specifica
- -
-
-
- 4-(3-Nitrophenyl)-2,3,5,6-pyridinetetracarboxylic acid and intermediates
-
4-(3-Nitrophenyl)pyridine, an intermediate useful in the preparation of 1-(lower-alkyl)-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylates, which are useful as anti-bacterial agents, is prepared by reacting 3-nitrobenzaldehyde with two molar equivalents of di-lower-alkyl) oxalacetate (II) in the presence of a catalytic condensing agent, preferably piperidine and/or its acetate, to produce tetra-(lower-alkyl) 3-(3-nitrophenyl)-1,5-pentanedione-1,2,4,5-tetracarboxylate (III), reacting III with ammonia to produce tetra-(lower-alkyl) 1,4-dihydro-4-(3-nitrophenyl)-2,3,5,6-pyridinetetracarboxylate (IV), oxidizing IV to produce tetra-(lower-alkyl) 4-(3-nitrophenyl)-2,3,5,6-pyridinetetracarboxylate (V), hydrolyzing V to produce 4-(3-nitrophenyl)-2,3,5,6-pyridinetetracarboxylic acid (VI) and decarboxylating VI to produce 4-(3-nitrophenyl)pyridine (VII). Intermediates III, IV, V and VI are novel.
- -
-
-